Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma

被引：0
|
作者：
Jamie E. Flerlage
Monika L. Metzger
Jianrong Wu
John C. Panetta
机构：
[1] The University of Tennessee Health Science Center,Department of Oncology, St. Jude Children’s Research Hospital
[2] The University of Tennessee Health Science Center,Department of Biostatistics, St. Jude Children’s Research Hospital
[3] The University of Tennessee Health Science Center,Pharmaceutical Sciences, St. Jude Children’s Research Hospital
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Brentuximab vedotin; Pharmacokinetics; Pediatric; Hodgkin lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1217 / 1223
页数：6
相关论文
共 50 条
  • [1] Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma
    Flerlage, Jamie E.
    Metzger, Monika L.
    Wu, Jianrong
    Panetta, John C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (06) : 1217 - 1223
  • [2] PHARMACOKINETICS, IMMUNOGENICITY AND SAFETY OF WEEKLY DOSING OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA
    Flerlage, J.
    Metzger, M.
    Panetta, J. C.
    HAEMATOLOGICA, 2016, 101 : 36 - 37
  • [3] A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma
    Oak, Eunhye
    Bartlett, Nancy L.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (06) : 875 - 882
  • [4] PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA PATIENTS AGED 60 AND ABOVE.
    Yang, J.
    Palanca-Wessels, M. C.
    Wang, Y.
    Josephson, N.
    Peng, S. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S85 - S85
  • [5] Brentuximab Vedotin for the Treatment of Patients with Hodgkin Lymphoma
    Younes, Anas
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (01) : 27 - +
  • [6] Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Gulati, Nitya
    Mauguen, Audrey
    Absalon, Michael J.
    Castellino, Sharon M.
    Franklin, Anna
    Keller, Frank G.
    Shukla, Neerav
    BLOOD ADVANCES, 2021, 5 (24) : 5519 - 5524
  • [7] Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
    Makita, Shinichi
    Maruyama, Dai
    Tobinai, Kensei
    ONCOTARGETS AND THERAPY, 2020, 13 : 5993 - 6009
  • [8] Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure-Response Analysis
    Zhou, Xiaofei
    Mould, Diane R.
    Gore, Lia
    Bai, Xiang
    Gupta, Neeraj
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,
  • [9] Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Vaklavas, Christos
    Forero-Torres, Andres
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (04) : 209 - 225
  • [10] BRENTUXIMAB VEDOTIN IS EFFECTIVE IN HODGKIN LYMPHOMA
    不详
    CANCER DISCOVERY, 2012, 2 (05) : 385 - 385
12345